Strategic Acquisition Evergen now operates under RTI Surgical after a 2024 acquisition, indicating potential alignment opportunities with RTI’s customer base and distribution network for collagen and biomaterials.

Regenerative Solutions With a broad portfolio spanning engineered tissue scaffolds, biomaterials, and medical devices used in orthopedics, cardiovascular, dental, wound care, and neurology, there are cross-sell opportunities to contractors and manufacturers in these high-demand sectors.

Scale & Capacity Recent facility expansions and manufacturing capacity investments suggest willingness to scale up production; target OEMs and research partners needing reliable supply of medical-grade collagen and tissues.

Technology Enablement Existing tech stack and digital presence indicate readiness for collaborative platforms, e-commerce enablement, and data-driven partnerships; leverage for streamlined procurement and technical co-development.

Funding & Growth Significant funding history and government grants underscore financial stability and growth momentum; position to pursue co-development grants, funded R&D collaborations, and long-term contract manufacturing arrangements.